These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24072415)

  • 41. Uremic Toxins Affecting Cardiovascular Calcification: A Systematic Review.
    Holmar J; de la Puente-Secades S; Floege J; Noels H; Jankowski J; Orth-Alampour S
    Cells; 2020 Nov; 9(11):. PubMed ID: 33172085
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expanded Haemodialysis as a Current Strategy to Remove Uremic Toxins.
    Ciceri P; Cozzolino M
    Toxins (Basel); 2021 May; 13(6):. PubMed ID: 34073439
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Toxicity of parathyroid hormone in uremia.
    Klahr S; Slatopolsky E
    Annu Rev Med; 1986; 37():71-8. PubMed ID: 3010810
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vasculopathy in the setting of cardiorenal syndrome: roles of protein-bound uremic toxins.
    Guo J; Lu L; Hua Y; Huang K; Wang I; Huang L; Fu Q; Chen A; Chan P; Fan H; Liu ZM; Wang BH
    Am J Physiol Heart Circ Physiol; 2017 Jul; 313(1):H1-H13. PubMed ID: 28411233
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular mechanisms underlying uremic toxin-related systemic disorders in chronic kidney disease: focused on β
    Yamamoto S
    Clin Exp Nephrol; 2019 Feb; 23(2):151-157. PubMed ID: 29869756
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease.
    Quaschning T; Krane V; Metzger T; Wanner C
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S14-9. PubMed ID: 11576915
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Contribution of Gut Microbiota-Derived Uremic Toxins to the Cardiovascular System Mineralization.
    Filipska I; Winiarska A; Knysak M; Stompór T
    Toxins (Basel); 2021 Apr; 13(4):. PubMed ID: 33920096
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lipoproteins in chronic kidney disease: from bench to bedside.
    Speer T; Ridker PM; von Eckardstein A; Schunk SJ; Fliser D
    Eur Heart J; 2021 Jun; 42(22):2170-2185. PubMed ID: 33393990
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sphingolipid imbalance and inflammatory effects induced by uremic toxins in heart and kidney cells are reversed by dihydroceramide desaturase 1 inhibition.
    Savira F; Magaye R; Scullino CV; Flynn BL; Pitson SM; Anderson D; Creek DJ; Hua Y; Xiong X; Huang L; Liew D; Reid C; Kaye D; Kompa AR; Wang BH
    Toxicol Lett; 2021 Oct; 350():133-142. PubMed ID: 34303789
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Accumulated uremic toxins attenuate bone mechanical properties in rats with chronic kidney disease.
    Iwasaki Y; Kazama JJ; Yamato H; Shimoda H; Fukagawa M
    Bone; 2013 Dec; 57(2):477-83. PubMed ID: 23920356
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cerebrovascular Disease, Cardiovascular Disease, and Chronic Kidney Disease: Interplays and Influences.
    Spence JD; Urquhart BL
    Curr Neurol Neurosci Rep; 2022 Nov; 22(11):757-766. PubMed ID: 36181576
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations.
    Noels H; Lehrke M; Vanholder R; Jankowski J
    Nat Rev Nephrol; 2021 Aug; 17(8):528-542. PubMed ID: 33972752
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease.
    Gryp T; De Paepe K; Vanholder R; Kerckhof FM; Van Biesen W; Van de Wiele T; Verbeke F; Speeckaert M; Joossens M; Couttenye MM; Vaneechoutte M; Glorieux G
    Kidney Int; 2020 Jun; 97(6):1230-1242. PubMed ID: 32317112
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Uremic toxins: some thoughts on acrolein and spermine.
    Sindhu KK
    Ren Fail; 2016 Nov; 38(10):1755-1758. PubMed ID: 27758122
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chronic kidney disease induced dysfunction of high density lipoprotein.
    Yamamoto S; Kon V
    Clin Exp Nephrol; 2014 Apr; 18(2):251-4. PubMed ID: 24018401
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Uremic Toxins and Vascular Dysfunction.
    Six I; Flissi N; Lenglet G; Louvet L; Kamel S; Gallet M; Massy ZA; Liabeuf S
    Toxins (Basel); 2020 Jun; 12(6):. PubMed ID: 32570781
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Exploring binding characteristics and the related competition of different protein-bound uremic toxins.
    Deltombe O; de Loor H; Glorieux G; Dhondt A; Van Biesen W; Meijers B; Eloot S
    Biochimie; 2017 Aug; 139():20-26. PubMed ID: 28528271
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120.
    Liu WC; Tomino Y; Lu KC
    Toxins (Basel); 2018 Sep; 10(9):. PubMed ID: 30208594
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Disorders of carbohydrate and lipid metabolism in uremia.
    Bagdade
    Nephron; 1975; 14(2):153-62. PubMed ID: 1093054
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Uremic toxicity: present state of the art.
    Vanholder R; Argilés A; Baurmeister U; Brunet P; Clark W; Cohen G; De Deyn PP; Deppisch R; Descamps-Latscha B; Henle T; Jorres A; Massy ZA; Rodriguez M; Stegmayr B; Stenvinkel P; Wratten ML
    Int J Artif Organs; 2001 Oct; 24(10):695-725. PubMed ID: 11817319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.